In a patient with chronic stable angina, which medication is more effective for long‑term symptom control, isosorbide (isosorbide mononitrate or dinitrate) or ranolazine (Ranexa)?

Ranolazine (Ranexa) and Isosorbide Show Similar Symptom Control, but Ranolazine Offers Distinct Advantages in Specific Clinical Scenarios

For chronic stable angina, ranolazine and isosorbide (long-acting nitrates) demonstrate equivalent efficacy for symptom control, but ranolazine is preferred when patients have bradycardia, hypotension, diabetes, left ventricular hypertrophy, or intolerance to hemodynamic effects of traditional agents. 1, 2

Evidence of Equivalence in Symptom Control

• A systematic review and Cochrane meta-analysis concluded that ranolazine (500-1000 mg extended-release) is effective in reducing symptoms of chronic stable angina, similarly to all other currently used antianginal agents including long-acting nitrates. 1

• A comprehensive systematic review covering 50 years of medical treatment found no evidence that any antianginal drug is superior to another for angina treatment or prolonging total exercise duration. 3

• The 2024 ESC guidelines classify both long-acting nitrates and ranolazine as second-line add-on therapies with the same level of recommendation (IIa, Level B). 2

When Ranolazine Is Superior: Clinical Scenarios

Hemodynamic Considerations

• Ranolazine's neutral hemodynamic profile makes it particularly useful in patients with bradycardia and/or hypotension, as it does not affect heart rate or blood pressure. 1 This contrasts with the potential for nitrates to cause hypotension and reflex tachycardia.

• Ranolazine reduces angina through prevention of calcium overload during ischemia, thereby reducing left ventricular wall tension without hemodynamic effects. 1, 4

Diabetes Mellitus

• In patients with diabetes and chronic stable angina, ranolazine significantly reduced glycated hemoglobin (HbA1c) levels in the MERLIN trial, providing dual benefit. 1

• A comparative effectiveness study demonstrated that ranolazine use in patients with inadequately controlled chronic angina and diabetes was associated with less revascularization and lower all-cause and cardiovascular-related healthcare utilization compared to traditional antianginal medications. 5

Left Ventricular Hypertrophy

• Given ranolazine's effects on sodium current and calcium homeostasis, it may be more effective than other drugs in patients with left ventricular hypertrophy. 1

Post-PCI Persistent Ischemia

• In patients with successful PCI who continue to have exercise-induced ischemia, ranolazine (375 mg bid) showed significantly longer time to 1 mm ST-segment depression compared to isosorbide-5-mononitrate (404±116 s vs. 322±70 s, p<0.01). 6

When Isosorbide May Be Preferred

Vasospastic Angina

• For vasospastic angina specifically, long-acting nitrates remain a first-line recommendation in guidelines. 7 The 2023 AHA/ACC guidelines recommend calcium channel blockers as first-line with addition of long-acting nitrates (such as isosorbide mononitrate 10 mg BID) as second-line therapy. 7

• However, a 2024 randomized controlled trial found that long-acting cilostazol provided more intensive control of vasospastic angina within 1 week compared to isosorbide mononitrate, with fewer neurological adverse reactions (headache: 30% vs. 70%, p=0.027). 8 This suggests nitrates may not be optimal even in this indication.

Cost and Availability

• Isosorbide preparations are generally less expensive and more widely available than ranolazine, which may be relevant in resource-limited settings.

Critical Safety Considerations

Ranolazine Contraindications and Precautions

• Ranolazine is contraindicated in patients with hepatic impairment or liver cirrhosis due to QTc prolongation risk. 1, 9

• Ranolazine causes dose-dependent QTc interval prolongation, though this does not appear to have clinical consequences at recommended therapeutic doses. 1

• Ranolazine is contraindicated with strong CYP3A inhibitors (ketoconazole, clarithromycin, ritonavir) and CYP3A inducers (rifampin, carbamazepine, phenytoin, St. John's wort). 9

• Ranolazine increases digoxin concentrations by 50% and should be used with caution in patients taking digoxin. 1, 9

• Patients with severe renal impairment may be at risk of renal failure while on ranolazine. 9

Isosorbide Considerations

• Nitrate tolerance is a well-recognized phenomenon with isosorbide preparations, though sustained-release formulations (Imdur) may have reduced tolerance development. 10

• Headache is the most common adverse effect of nitrates, occurring more frequently than with ranolazine (70% vs. 30% in one comparative study). 8

• Abrupt discontinuation of long-term isosorbide treatment may exacerbate anginal symptoms. 10

Important Mortality and Morbidity Data

• Ranolazine does not improve hard outcomes (death, myocardial infarction, or need for revascularization) in patients with chronic stable angina. 1 The RIVER-PCI trial showed no improvement in the primary endpoint of death, MI, or recurrent angina requiring revascularization. 1

• Similarly, the MERLIN trial found no beneficial effects on major cardiovascular events in patients with non-ST-segment elevation acute coronary syndrome. 1

• Neither ranolazine nor isosorbide improve mortality or prevent myocardial infarction—both are purely symptomatic therapies. 1

Practical Dosing Algorithm

For Ranolazine:

• Start at 500 mg twice daily, may increase to 1000 mg twice daily based on symptom response. 9
• Maximum dose is 1000 mg twice daily; higher doses should not be used. 9
• Take with or without food; swallow tablets whole. 9

For Isosorbide Mononitrate:

• Sustained-release formulations: 60 mg once daily in the morning provides effective prophylaxis throughout the day. 10
• Conventional formulations: 20 mg twice daily. 11, 8
• Dosage flexibility may be needed based on individual variation (20-40 mg twice daily). 11

Clinical Decision Framework

Choose ranolazine when:

• Patient has bradycardia or hypotension limiting use of beta-blockers or calcium channel blockers 1
• Patient has diabetes mellitus (dual benefit on HbA1c) 1, 5
• Patient has left ventricular hypertrophy 1
• Patient has persistent ischemia post-PCI 6
• Patient cannot tolerate nitrate-induced headaches 8

Choose isosorbide when:

• Patient has vasospastic angina (though evidence is evolving) 7
• Cost is a primary concern
• Patient has hepatic impairment (ranolazine contraindicated) 1, 9
• Patient is on strong CYP3A inhibitors or inducers (ranolazine contraindicated) 9

Both are equivalent when:

• Patient has uncomplicated chronic stable angina without the above specific features 1, 3
• Patient requires add-on therapy to beta-blockers or calcium channel blockers 2